Alaunos Therapeutics to Present Data High…
Data supports high-throughput screening process to identify neoantigen-reactive TCRs
Exclusive ownership of discovered KRAS mutation-reactive TCRs hunTR enables expansion of the Company’s hotspot mutation targeted TCR library
HOUSTON, Nov. 07, 2022 (GLOBE NEWSWIRE) — Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), a clinical-stage oncology-focused cell therapy company today announced a poster presentation highlighting…
Alaunos Therapeutics, Inc. has recently announced significant advancements in their high-throughput screening process to identify neoantigen-reactive TCRs. This innovative approach allows the company to exclusively own discovered KRAS mutation-reactive TCRs, enhancing their hotspot mutation targeted TCR library.
By utilizing hunTR, Alaunos is able to expand their library of T cell receptors that target specific hotspot mutations, which could potentially revolutionize the field of oncology-focused cell therapy. The poster presentation highlights the promising data that supports this groundbreaking process.
Impact on Individuals:
The development of high-throughput screening to identify neoantigen-reactive TCRs could have a significant impact on individuals diagnosed with cancer. By targeting specific mutations with precision, personalized cell therapy treatments may become more effective, offering hope to patients who previously had limited treatment options.
Impact on the World:
Alaunos Therapeutics’ innovative approach to identifying and owning discovered TCRs has the potential to transform the landscape of oncology treatment worldwide. By expanding their library of mutation-reactive TCRs, they are paving the way for more targeted therapies that could improve outcomes and pave the way for advancements in cancer treatment globally.
Conclusion:
Alaunos Therapeutics’ presentation of data supporting their high-throughput screening process marks a significant milestone in the field of oncology-focused cell therapy. The exclusive ownership of discovered KRAS mutation-reactive TCRs and the expansion of their targeted TCR library hold great promise for both individuals seeking innovative cancer treatments and the global landscape of oncology research and development.
